Maxime Fontanilles1,2, Alberto Duran-Peña2, Ahmed Idbaih3. 1. Normandie Univ, UNIROUEN, Inserm U1245, IRON Group, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, F-76031, Rouen, France. 2. AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013, Paris, France. 3. Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013, Paris, France. ahmed.idbaih@aphp.fr.
Abstract
PURPOSE OF REVIEW: Personalized medicine is a challenge to improve survival and quality of life of patients suffering from primary malignant brain tumor. Molecular biology is integrated in initial diagnosis and relapse, and, in the nearest future, over treatment schedule and monitoring. Liquid biopsy is a minimally invasive way to obtain tumor material. RECENT FINDINGS: Over the past years, three fluids have been explored to provide tumor information in primary malignant brain tumor: blood, cerebrospinal fluid, and vitreous liquid. Different tumor components were identified: (1) circulating tumor cells, (2) circulating tumor DNA, (3) RNA and non-coding miRNA, and (4) extracellular vesicles. The performance of the liquid biopsy depends on the tumor type and on the method of detection. Liquid biopsy could be a valuable tool to improve patient care in primary malignant brain tumor. Improvement of its sensitivity is the major challenge to generalize its use in daily practice.
PURPOSE OF REVIEW: Personalized medicine is a challenge to improve survival and quality of life of patients suffering from primary malignant brain tumor. Molecular biology is integrated in initial diagnosis and relapse, and, in the nearest future, over treatment schedule and monitoring. Liquid biopsy is a minimally invasive way to obtain tumor material. RECENT FINDINGS: Over the past years, three fluids have been explored to provide tumor information in primary malignant brain tumor: blood, cerebrospinal fluid, and vitreous liquid. Different tumor components were identified: (1) circulating tumor cells, (2) circulating tumor DNA, (3) RNA and non-coding miRNA, and (4) extracellular vesicles. The performance of the liquid biopsy depends on the tumor type and on the method of detection. Liquid biopsy could be a valuable tool to improve patient care in primary malignant brain tumor. Improvement of its sensitivity is the major challenge to generalize its use in daily practice.
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt Journal: Nat Med Date: 2015-07-20 Impact factor: 53.440
Authors: Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz Journal: Nat Med Date: 2007-07-31 Impact factor: 53.440
Authors: S Hohaus; M Giachelia; G Massini; G Mansueto; B Vannata; V Bozzoli; M Criscuolo; F D'Alò; M Martini; L M Larocca; M T Voso; G Leone Journal: Ann Oncol Date: 2009-05-22 Impact factor: 32.976
Authors: Inga Medina Diaz; Annette Nocon; Daniel H Mehnert; Johannes Fredebohm; Frank Diehl; Frank Holtrup Journal: PLoS One Date: 2016-11-10 Impact factor: 3.240
Authors: A K Krug; D Enderle; C Karlovich; T Priewasser; S Bentink; A Spiel; K Brinkmann; J Emenegger; D G Grimm; E Castellanos-Rizaldos; J W Goldman; L V Sequist; J-C Soria; D R Camidge; S M Gadgeel; H A Wakelee; M Raponi; M Noerholm; J Skog Journal: Ann Oncol Date: 2018-03-01 Impact factor: 32.976
Authors: Ying Meng; Christopher B Pople; Dan Budiansky; Daniel Li; Suganth Suppiah; Mary Jane Lim-Fat; James Perry; Arjun Sahgal; Nir Lipsman Journal: J Neurooncol Date: 2021-10-18 Impact factor: 4.130
Authors: Anna Estival; Carolina Sanz; Jose-Luis Ramirez; Jose Maria Velarde; Marta Domenech; Cristina Carrato; Ramón de Las Peñas; Miguel Gil-Gil; Juan Sepúlveda; Roser Armengol; Isaac Cardiel; Alfonso Berrocal; Raquel Luque; Ana Herrero; Carmen Balana Journal: Sci Rep Date: 2019-07-31 Impact factor: 4.379
Authors: Thais S Sabedot; Tathiane M Malta; James Snyder; Kevin Nelson; Michael Wells; Ana C deCarvalho; Abir Mukherjee; Dhananjay A Chitale; Maritza S Mosella; Artem Sokolov; Karam P Asmaro; Adam Robin; Mark L Rosenblum; Tom Mikkelsen; Jack Rock; Laila M Poisson; Ian Lee; Tobias Walbert; Steven Kalkanis; Antonio Iavarone; Ana Valeria Castro; Houtan Noushmehr Journal: Neuro Oncol Date: 2021-09-01 Impact factor: 12.300
Authors: Olga A Sindeeva; Roman A Verkhovskii; Mustafa Sarimollaoglu; Galina A Afanaseva; Alexander S Fedonnikov; Evgeny Yu Osintsev; Elena N Kurochkina; Dmitry A Gorin; Sergey M Deyev; Vladimir P Zharov; Ekaterina I Galanzha Journal: Cells Date: 2019-10-02 Impact factor: 7.666